Colon Cancer: Who Can Receive Adjuvant Atezolizumab?
Source announcement: . Published by iMedic on October 10, 2026.
Quick Facts
Key takeaways
- Tumor stage and mismatch-repair status both matter.
- Disease-free survival is not the same as a cure rate.
Who is eligible under the announcement?
The FDA decision covers intravenous Tecentriq from age two. The subcutaneous combination has different criteria: age at least 12 and weight at least 40 kg.
What did the trial find?
ATOMIC enrolled 711 adults and one pediatric patient. The hazard ratio was 0.50, with a 95% confidence interval of 0.35–0.73. Median disease-free survival was not reached in either group.
How should patients interpret that result?
A hazard ratio cannot be read as the proportion of people cured or as a guaranteed survival extension. Ask the oncology team how the trial population and biomarker testing apply to the individual case. The FDA also lists immune-mediated and infusion-related risks.
Frequently Asked Questions
No; the announcement specifies stage III dMMR disease.
The described setting is after complete tumor resection.
No. Their age and weight criteria differ.
No.
The pathology, mismatch-repair result and oncology treatment plan.
References
- FDA approval and ATOMIC results. Source checked October 10, 2026.
How was this news summary prepared?
iMedic Editorial Team checked this summary against the primary sources linked above. It reports a dated announcement and its limitations; it is not an individual treatment recommendation. Editorial standards.